Natalizumab-treated patients with multiple sclerosis are at high risk of Progressive Multifocal Leukoencephalopathy persistently excrete JC polyomavirus (JCV) viruria.
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2018
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 18 Mar 2018 New trial record